2413.01(d) The âSequence Listing XMLâ Must Contain a DOCTYPE Declaration [R-07.2022]
2413.01(d) The “Sequence Listing XML” Must Contain a DOCTYPE Declaration [R-07.2022]
[Editor Note: This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b). Formatting representations of XML (eXtensible Markup Language) elements in this section appear different than shown in Standard ST.26, which may be accessed at: www.wipo.int/export/sites/www/standards/en/pdf/03-26-01.pdf.]
37 CFR 1.833 Requirements for a “Sequence Listing XML” for nucleotide and/or amino acid sequences as part of a patent application filed on or after July 1, 2022.
-
*****
- (b) The “Sequence Listing XML” presented in accordance with paragraph (a) of this section must further:
-
*****
- (2) Comply with the requirements of WIPO Standard ST.26 to include:
-
*****
- (ii) A document type (DOCTYPE) declaration as defined in paragraph 39(b) of WIPO Standard ST.26;
-
-
-
*****
WIPO Standard ST.26, paragraph 39(b), specifies that the second line of the XML instance must contain the document type (DOCTYPE) declaration, which is:
<!DOCTYPE ST26SequenceListing PUBLIC “-//WIPO//DTD Sequence Listing 1.3//EN” “ST26SequenceListing_V1_3.dtd”>